Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Dong Won Baek, MD, Hee Jeong Cho, Sang Kyun Sohn, MD PhD, Sung-Hoon Jung, MD, Hong chae Moon, Joon Ho Moon, MD

Blood (2019) 134 (Supplement_1): 3142.

https://doi.org/10.1182/blood-2019-129831

Published: 2019

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Joon Ho Moon, MD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD PhD, Sang Kyun Sohn, MD PhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2018-99-116241

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

Journal Articles

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Ho-Young Yhim, MD PhD, Yong Park, MD, Joon Ho Moon, MD, Ho-Jin Shin, MD PhD, Yoon Seok Choi, MD, Min Kyoung Kim, MD PhD, Dae Sik Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Jun Soo Ham, MD, Seok Jin Kim, MD PhD, Won Seog Kim, MD PhD, Deok-Hwan Yang, MD, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2018-99-115620

Published: 2018

Journal Articles

Next Generation Sequencing (NGS)-Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeoung Kim, Seung-Shin Lee, MD, Seo-Yeon Ahn, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Myung-Geun Shin, MD PhD, Hoon Kook, MD PhD, Sun-Hee Kim, MD, Seong Kyu Park, MD, Hyeoung-Joon Kim, Zhaolei Zhang, PhD, Dennis (Dong-Hwong) Kim, MD PhD

Blood (2017) 130 (Supplement 1): 271.

https://doi.org/10.1182/blood.V130.Suppl_1.271.271

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeoung Kim, Seung-Shin Lee, MD, Seo-Yeon Ahn, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD, Sang Kyun Sohn, MDPhD, Yoo Hong Min, MD PhD, June-Won Cheong, MDPhD, Hyeoung-Joon Kim, Zhaolei Zhang, PhD, Dennis (Dong-Hwong) Kim, MD PhD

Blood (2017) 130 (Supplement 1): 3955.

https://doi.org/10.1182/blood.V130.Suppl_1.3955.3955

Published: 2017

Journal Articles

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

Yunsuk Choi, MD PhD, Ho Sup Lee, MD PhD, Je-Hwan Lee, MD, Joon Ho Moon, MD, PhD, Ho-Jin Shin, MD PhD, Won Sik Lee, MD PhD

Blood (2016) 128 (22): 3393.

https://doi.org/10.1182/blood.V128.22.3393.3393

Published: 2016

Journal Articles

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Blood (2016) 128 (22): 5253.

https://doi.org/10.1182/blood.V128.22.5253.5253

Published: 2016

Journal Articles

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Blood (2016) 128 (22): 52.

https://doi.org/10.1182/blood.V128.22.52.52

Published: 2016

Journal Articles

Efficacy of G-CSF Primed DLI Using Cells Reserved at the Time of Harvest in Patients with Hematologic Malignancies Who Lately Relapsed after Allogeneic PBSCT

YooJin Lee, MD, Joon Seok Yoon, In Hee Lee, MD, Joon Ho Moon, MD, PhD, Sang Kyun Sohn, MD, PhD

Blood (2016) 128 (22): 5809.

https://doi.org/10.1182/blood.V128.22.5809.5809

Published: 2016

Journal Articles

Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype

Blood (2016) 128 (22): 2876.

https://doi.org/10.1182/blood.V128.22.2876.2876

Published: 2016

Journal Articles

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Yoo Jin Lee, MD, Joon Ho Moon, MD, PhD, In Hee Lee, MD, Jae-Ho Yoon, Byung-Sik Cho, Jae-Sook Ahn, MD PhD, Hyeoung Joon Kim, MD PhD, Silvia Park, Jun Ho Jang, MD PhD, Chul Won Jung, MD PhD, Hyunsung Park, MD, June-Won Cheong, MD, Je-Hwan Lee, MD PhD, Sang Kyun Sohn, MD, PhD, Hee-Je Kim

Blood (2016) 128 (22): 4566.

https://doi.org/10.1182/blood.V128.22.4566.4566

Published: 2016

Journal Articles

The Clonal Origins of Leukemic Progression of Myelodysplasia

Taehyung Kim, MSc, Marc Tyndel, Hyeoung Joon Kim, MD, Jae-Sook Ahn, MD PhD, Seung Hyun Choi, PhD, Hee Jeong Park, Yeo-Kyeoung Kim, MD PhD, Deok-Hwan Yang, Je-Jung Lee, Sung-Hoon Jung, Soo Young Kim, Yoo-Hong Min, June-Won Cheong, MD, Sang Kyun Sohn, MD, PhD, Joon Ho Moon, MD, PhD, Murim Choi, Moses Lee, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 4307.

https://doi.org/10.1182/blood.V128.22.4307.4307

Published: 2016

Journal Articles

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Hyewon Lee, MD, Yu Ri Kim, Soo-Jeong Kim, MD, Yong Park, MD PhD, Hyeon-Seok Eom, Sung Yong Oh, MD, Hyo Jung Kim, Hye Jin Kang, Won-Sik Lee, Joon Ho Moon, MD, PhD, Young-Woong Won, MD PhD, Myung Hee Chang, Hye In Park, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4205.

https://doi.org/10.1182/blood.V128.22.4205.4205

Published: 2016

Journal Articles

Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements

Deok-Hwan Yang, MD PhD, Joon Ho Moon, MD, PhD, Seung-Shin Lee, MD, Jung-Joon Min, MD, Shin-Young Jeong, MD PhD, Yoo-Jin Lee, MD, Sung-Woo Park, MD, Yee Soo Chae, MD, Young Rok Do, Hyeoung-Joon Kim, MD PhD, Je-Jung Lee

Blood (2015) 126 (23): 1446.

https://doi.org/10.1182/blood.V126.23.1446.1446

Published: 2015

Journal Articles

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Hawk Kim, MD PhD, Je-Hwan Lee, MD PhD, Won-Sik Lee, MD, Inho Kim, Joon Ho Moon, MD, PhD, Chul Won Choi, MD PhD, Ho Sup Lee, MD PhD, Jinny Park, Ho-Jin Shin, Kyoung Ha Kim, MD, Su-Hee Cho, MD PhD, Sung-Yong Kim, MD, Yoo-Jin Kim

Blood (2015) 126 (23): 1687.

https://doi.org/10.1182/blood.V126.23.1687.1687

Published: 2015

NARROW

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Next Generation Sequencing (NGS)-Based Post-Transplant Monitoring in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Efficacy of G-CSF Primed DLI Using Cells Reserved at the Time of Harvest in Patients with Hematologic Malignancies Who Lately Relapsed after Allogeneic PBSCT

Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

The Clonal Origins of Leukemic Progression of Myelodysplasia

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only